Details of the Drug Reposition

General Information of This Drug (ID: DMPN5IH)

Drug Name
Guanfacine   DMPN5IH
Synonyms
GUANFACINE; Tenex; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; Estulic; Intuniv; N-amidino-2-(2,6-dichlorophenyl)acetamide; CHEBI:5558; INJOMKTZOLKMBF-UHFFFAOYSA-N; SPD 503; C9H9Cl2N3O; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; Guanfacine Monohydrochloride; NCGC00015469-05; Lon798; Guanfacine (INN); Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; Prestwick1_000339; Prestwick3_000339; Prestwick2_000339; Prestwick0_000339; Lopac-G-1043
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Attention deficit hyperactivity disorder DISL8MX9 6A05.Z Approved [1]
Alzheimer disease DISF8S70 8A20 Approved [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
High blood pressure DISY2OHH BA00 Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Guanfacine FDA Label
2 ClinicalTrials.gov (NCT03116126) Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT01368887) Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis. U.S. National Institutes of Health.